评估乳腺癌患者和无癌对照者的血清 Amphiregulin 水平。
Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls.
机构信息
Departments of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
出版信息
Exp Hematol Oncol. 2013 Sep 8;2(1):25. doi: 10.1186/2162-3619-2-25.
BACKGROUND
Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.
FINDINGS
Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.
CONCLUSIONS
Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.
背景
表皮生长因子受体配体 Amphiregulin 的表达与雌激素受体阳性乳腺癌相关。由于 Amphiregulin 可从乳腺癌细胞表面蛋白水解释放，因此我们检测了乳腺癌患者和非癌症女性血清中的 Amphiregulin 水平，以评估其作为乳腺癌生物标志物的潜在用途。
结果
通过 ELISA 从 125 名非癌症女性和 114 名乳腺癌患者中定量了血清 Amphiregulin 水平。在评估的两个截断值处，血清 Amphiregulin 水平与乳腺癌状态之间未发现显著关联。
结论
在一般人群中，测量血清 Amphiregulin 水平缺乏乳腺癌筛查的必要灵敏度和特异性。
Zotero 插件